
CorriXR Secures $1M Investment to Advance Gene-Editing Cancer Therapies
NEWARK, DE — CorriXR Therapeutics, Inc. has secured a $1 million investment from the State of Delaware to accelerate its development of next-generation treatments for solid tumors, including head and …
CorriXR Secures $1M Investment to Advance Gene-Editing Cancer Therapies Read More